Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade™ in patients with rheumatoid arthritis

Rheumatology

Volumn 40, Issue 5, 2001, Pages 537-543

  Hemmings, F J ^a   Farhan, M ^a   Rowland, J ^a   Banken, L ^b   Jain, R ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Collagenase selective inhibitor; Pharmacokinetics; Rheumatoid arthritis; Safety; Trocade

Indexed keywords

CIPEMASTAT; COLLAGENASE INHIBITOR; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSURIA; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; INFECTION; LABORATORY TEST; LOW BACK PAIN; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; SORE THROAT; URTICARIA;

EID: 0034980670     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/40.5.537     Document Type: Article

References (15)

1. Monitoring radiographic changes in early rheumatoid arthritis
2. Long-term outcome in rheumatoid arthritis
3. Disease controlling anti-rheumatic therapy: Preventing or significantly decreasing the rate of progression of structural damage
4. Total knee arthroplasty: A population-based study
5. Prevention of cartilage breakdown by matrix metalloproteinase inhibition-a realistic therapeutic target?
6. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
7. Articular cartilage
8. Mechanisms of joint destruction and therapeutic approaches
9. Using inhibitors of metalloproteinases to treat arthritis
10. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo
11. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis
12. Cartilage protection agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis
13. Absolute bioavailability of the collagenase selective (CSI) inhibitor, Trocade™, is unaffected by food
14. Pharmacokinetics and metabolism of the collagenase-selective inhibitor (CSI), Cipemastat (Ro 32-3555)
15. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor Marimastat in gastric cancer